Filtros de búsqueda

Lista de obras de Eva Havrdová

044 Durable clinical efficacy of alemtuzumab in patients with active rrms in the absence of continuous treatment: 7-year follow-up of CARE-MS I patients (Topaz Study)

artículo científico publicado en 2018

A Novel Semiautomated Pipeline to Measure Brain Atrophy and Lesion Burden in Multiple Sclerosis: A Long-Term Comparative Study

artículo científico publicado en 2017

A Serial 10-Year Follow-Up Study of Atrophied Brain Lesion Volume and Disability Progression in Patients with Relapsing-Remitting MS

scientific article published on 28 February 2019

A serial 10-year follow-up study of brain atrophy and disability progression in RRMS patients

artículo científico publicado en 2016

ALEMTUZUMAB IMPROVES 3-YEAR QUALITY OF LIFE IN CARE-MS II

artículo científico publicado en 2015

ALEMTUZUMAB PERSISTENTLY SLOWS BRAIN VOLUME LOSS IN RRMS

artículo científico publicado en 2016

Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS

artículo científico publicado en 2011

Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy

artículo científico publicado en 2017

Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings

artículo científico publicado en 2017

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

artículo científico publicado en 2012

Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients

artículo científico publicado en 2016

Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis

artículo científico publicado en 2016

Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use

artículo científico publicado en 2015

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

artículo científico publicado en 2012

Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS.

artículo científico publicado en 2017

Apolipoproteins are associated with new MRI lesions and deep grey matter atrophy in clinically isolated syndromes

artículo científico publicado en 2014

Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis

scientific article published on 01 January 2019

Bimonthly Evolution of Cortical Atrophy in Early Relapsing-Remitting Multiple Sclerosis over 2 Years: A Longitudinal Study.

artículo científico publicado en 2013

Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis.

artículo científico publicado en 2017

Clinical Significance of Gastrointestinal and Flushing Events in Patients with Multiple Sclerosis Treated with Delayed-Release Dimethyl Fumarate

artículo científico publicado en 2015

Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the CONFIRM study

artículo científico publicado en 2013

Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium

artículo científico publicado en 2020

Combining clinical and magnetic resonance imaging markers enhances prediction of 12-year disability in multiple sclerosis

artículo científico publicado en 2016

Combining clinical and magnetic resonance imaging markers enhances prediction of 12-year employment status in multiple sclerosis patients

scientific article published on 06 March 2018

Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom ⬇️

artículo científico publicado en 2022

Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis

artículo científico publicado en 2014

Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis

artículo científico publicado en 2015

Contribution of different relapse phenotypes to disability in multiple sclerosis.

artículo científico publicado en 2016

Country, sex, EDSS change and therapy choice independently predict treatment discontinuation in multiple sclerosis and clinically isolated syndrome

artículo científico publicado en 2012

Cross cultural validation of the Minimal Assessment of Cognitive Function in Multiple Sclerosis (MACFIMS) and the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS).

artículo científico publicado en 2012

DACLIZUMAB HYP IN MULTIPLE SCLEROSIS: 3-YEAR RESULTS FROM SELECTED

artículo científico publicado en 2016

DACLIZUMAB HYP VS IM INTERFERON BETA-1A IN MS: NEDA RESULTS FROM DECIDE

artículo científico publicado en 2016

Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis

artículo científico publicado en 2015

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial ⬇️

artículo científico publicado el 4 de abril de 2013

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial

artículo científico publicado en 2014

Defining reliable disability outcomes in multiple sclerosis

artículo científico publicado en 2015

Defining secondary progressive multiple sclerosis

artículo científico publicado en 2016

Delayed-Release Dimethyl Fumarate and Pregnancy: Preclinical Studies and Pregnancy Outcomes from Clinical Trials and Postmarketing Experience

artículo científico publicado en 2015

Detection of cortical lesions is dependent on choice of slice thickness in patients with multiple sclerosis

artículo científico publicado en 2007

Development of gray matter atrophy in relapsing-remitting multiple sclerosis is not gender dependent: results of a 5-year follow-up study.

artículo científico publicado en 2013

Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria

artículo científico publicado en 2011

Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis

artículo científico publicado en 2020

Disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with daclizumab high-yield process in the SELECT study

artículo científico publicado en 2013

ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis

artículo científico publicado en 2018

Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis

artículo científico publicado en 2013

Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study

artículo científico publicado en 2009

Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM study

artículo científico publicado en 2013

Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study

artículo científico publicado en 2015

Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison

artículo científico publicado en 2013

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

artículo científico publicado en 2008

Environmental factors associated with disease progression after the first demyelinating event: results from the multi-center SET study

artículo científico publicado en 2013

Freedom from disease activity in multiple sclerosis

artículo científico publicado en 2010

Gray matter atrophy and disability progression in patients with early relapsing-remitting multiple sclerosis: a 5-year longitudinal study

artículo científico publicado en 2009

Guidelines for uniform reporting of body fluid biomarker studies in neurologic disorders

artículo científico publicado en 2014

HLA DRB1*1501 is only modestly associated with lesion burden at the first demyelinating event

artículo científico publicado en 2011

Health-related quality of life in multiple sclerosis: effects of natalizumab

artículo científico publicado en 2007

Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis.

artículo científico publicado en 2016

Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis

artículo científico publicado en 2016

Humoral responses to herpesviruses are associated with neurodegeneration after a demyelinating event: results from the multi-center set study

artículo científico publicado en 2014

Impact of daclizumab versus interferon beta-1a on patient-reported outcomes in relapsing-remitting multiple sclerosis

artículo científico publicado en 2016

Increased albumin quotient (QAlb) in patients after first clinical event suggestive of multiple sclerosis is associated with development of brain atrophy and greater disability 48 months later

artículo científico publicado en 2015

Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study

artículo científico publicado en 2018

Integrating an evidence-based assessment of benefit and risk in disease-modifying treatment of multiple sclerosis

artículo científico publicado en 2007

Integration of genetic risk factors into a clinical algorithm for multiple sclerosis susceptibility: a weighted genetic risk score

artículo científico publicado en 2009

Interactions of serum cholesterol with anti-herpesvirus responses affect disease progression in clinically isolated syndromes

artículo científico publicado en 2013

Interferon Beta Use and Disability Prevention in Relapsing-Remitting Multiple Sclerosis

artículo científico publicado en 2013

Interferon-β or azathioprine as add-on therapies in patients with active multiple sclerosis

artículo científico publicado en 2012

Is no evidence of disease activity an achievable goal in MS patients on intramuscular interferon beta-1a treatment over long-term follow-up?

artículo científico publicado en 2016

Lipid profiles are associated with lesion formation over 24 months in interferon-β treated patients following the first demyelinating event

artículo científico publicado en 2013

Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis

artículo científico publicado en 2017

Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis

artículo científico publicado en 2017

Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study

artículo científico publicado en 2016

Longitudinal MRI and neuropsychological assessment of patients with clinically isolated syndrome

artículo científico publicado en 2014

Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod

artículo científico publicado en 2017

Lymphocyte subset dynamics following alemtuzumab treatment in patients who relapsed on a prior therapy

artículo científico publicado en 2014

MANAGEMENT OF ADVERSE REACTIONS TO ALEMTUZUMAB INFUSION

artículo científico publicado en 2015

MRI correlates of disability progression in patients with CIS over 48 months

artículo científico publicado en 2014

Managing flushing and gastrointestinal events associated with delayed-release dimethyl fumarate: Experiences of an international panel

artículo científico publicado en 2014

MxA mRNA decrease preceding NAb detection in IFNβ-treated MS patients.

artículo científico

Myxovirus Resistance Protein A mRNA Expression Kinetics in Multiple Sclerosis Patients Treated with IFNβ.

artículo científico publicado en 2017

Natalizumab promotes anti-inflammatory and repair effects in multiple sclerosis

artículo científico publicado en 2024

Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring

artículo científico publicado en 2007

Neurofilament light chain and oligoclonal bands are prognostic biomarkers in radiologically isolated syndrome

artículo científico publicado en 2018

Neutralising antibodies to interferon beta in multiple sclerosis : expert panel report

artículo científico publicado en 2007

No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a

artículo científico publicado en 2018

No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study

artículo científico publicado en 2016

Oral BG-12 (dimethyl fumarate) for relapsing-remitting multiple sclerosis: a review of DEFINE and CONFIRM. Evaluation of: Gold R, Kappos L, Arnold D, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Me

artículo científico

Oral BG-12 in Multiple Sclerosis ⬇️

artículo científico publicado el 25 de abril de 2013

Patients' stratification and correlation of brain magnetic resonance imaging parameters with disability progression in multiple sclerosis

artículo científico publicado en 2009

Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis ⬇️

artículo científico publicado el 20 de septiembre de 2012

Predictors of long-term disability accrual in relapse-onset multiple sclerosis

artículo científico publicado en 2016

Pregnancy Experience: Nonclinical Studies and Pregnancy Outcomes in the Daclizumab Clinical Study Program

scientific article published on 13 July 2016

Protective associations of HDL with blood-brain barrier injury in multiple sclerosis patients.

artículo científico publicado en 2015

Quantification of Gait Abnormalities in Healthy-Looking Multiple Sclerosis Patients (with Expanded Disability Status Scale 0-1.5)

artículo científico publicado en 2016

Quantifying risk of early relapse in patients with first demyelinating events: Prediction in clinical practice.

artículo científico publicado en 2016

Real-Life Outcome in Multiple Sclerosis in the Czech Republic

artículo científico publicado en 2019

Recommendations for the use of prolonged-release fampridine in patients with multiple sclerosis (MS).

artículo científico publicado en 2013

Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study

artículo científico publicado en 2012

Relapses Requiring Intravenous Steroid Use and Multiple-Sclerosis-related Hospitalizations: Integrated Analysis of the Delayed-release Dimethyl Fumarate Phase III Studies

artículo científico

Relationship between gray matter volume and cognitive learning in CIS patients on disease-modifying treatment

artículo científico publicado en 2014

Reliable measurements of brain atrophy in individual patients with multiple sclerosis.

artículo científico publicado en 2016

Reply to: Comment on Y.D. Fragoso et al.: "Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod" [Mult. Scler. Relat. Disord. (2017)]

scientific article published on 24 February 2018

Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study

artículo científico publicado en 2016

Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab

artículo científico publicado en 2012

Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study.

artículo científico publicado en 2016

Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: a phase 2 study

artículo científico publicado en 2014

Secondary-progressive form of multiple sclerosis: MRI changes versus clinical status.

artículo científico publicado en 2008

Serological analysis of complement in patients with neuromyelitis optica

scholarly article by Petra Nytrova et al published November 2012 in Immunobiology

Serum lipid profile changes predict neurodegeneration in interferon-β1a-treated multiple sclerosis patients.

artículo científico publicado en 2016

Serum lipoprotein composition and vitamin D metabolite levels in clinically isolated syndromes: Results from a multi-center study

artículo científico publicado en 2014

Should rapid decrease of NK cells be marker of conversion from CIS to CDMS?

artículo científico publicado en 2014

Spatial and temporal characteristics of gait as outcome measures in multiple sclerosis (EDSS 0 to 6.5).

artículo científico publicado en 2015

Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MS.

artículo científico publicado en 2016

Survey of diagnostic and treatment practices for multiple sclerosis in Europe, part 2: progressive MS, paediatric MS, pregnancy and general management

artículo científico publicado en 2018

Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis

artículo científico publicado en 2015

The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis

artículo científico publicado en 2016

The clinical meaning of walking speed as measured by the timed 25-foot walk in patients with multiple sclerosis.

artículo científico publicado en 2014

The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis

artículo científico publicado en 2015

The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL

artículo científico publicado en 2009

The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL.

artículo científico publicado en 2009

Therapeutic considerations for disease progression in multiple sclerosis: evidence, experience, and future expectations

artículo científico publicado en 2005

Timing of high-efficacy therapy in relapsing-remitting multiple sclerosis: A systematic review

artículo científico publicado en 2017

Towards personalized therapy for multiple sclerosis: prediction of individual treatment response.

artículo científico publicado en 2017

Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study.

artículo científico publicado en 2017

Understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program

artículo científico publicado en 2017

Volumetric MRI markers and predictors of disease activity in early multiple sclerosis: a longitudinal cohort study

artículo científico publicado en 2012

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda